Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

By Risto Kerkelä, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, Cara Beahm, B. Walters, S. Shevtsov, S. Pesant, F. Clubb and 6 more. Nature Medicine, 2006

1,184 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/2590cc4bbf3f1001bf07cdf5b60fd5fc784c5d6d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. J. Cortes
2. J. Apperley
3. Andreas Hochhaus
4. J. Goldman
5. H. Kantarjian
6. M. Baccarani
7. Brian J. Druker

In Molecular Biology

1. A. Hopkins
2. Aki Vehtari
3. Yibin Wang
4. B. Rose
5. T. Force
6. Roderick E. Hubbard

In Rheumatology

1. J. Cortes
2. Andreas Hochhaus
3. H. Kantarjian
4. M. Baccarani
5. Brian J. Druker

Citations in the corpus

• Network pharmacology: the next paradigm in drug discovery. (2008, background): “However, imatinib also inhibits the non-oncogenic C-Abl kinase in normal cells, and long-term administration of the drug can lead to cardiotoxicit”
• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (2013, background): “The third category includes late, so-called “off-target” complications, which can affect the cardiovascular system, heart and blood vessels, the respiratory system, liver, pancreas, the immune defense, second malignancies, calcium, glucose, and lipid metabolism, etc.(144-159) All TKIs can be toxic t”
• Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. (2010, background): “For example, Kerkela and co-workers (127, 199) have found that ER stress and ensuing JNK activation is responsible for mitochondrial defects and severe cardiomyopathy as a result of anticancer therapy targeted to the tyrosine kinase c-abl.”
• Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. (2009, background): “Imatinib may induce cardiotoxicity through inhiition of c-Abl (33,43).”
• One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. (2012, background): “Primary tumor diameter, median (range), cm 9 (2-35) 10 (2-40)”
• Pulmonary arterial hypertension (2013, background): “In addition, it has been demonstrated that tyrosine kinase inhibitors, including imatinib, may have possible cardiac adverse effects on long term use that might limit its benefice in PAH [269].”
• The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. (2007, background): “Given its invasive nature, EMB in patients treated with chemotherapeutic agents may be best suited for situations in which there is question as to the cause of cardiac dysfunction (76), as well as in select cases in which ultimate administration of greater than the usual upper limit of an agent is b”